Agilent (A) Up 9.6% Since Last Earnings Report: Can It Continue?

Agilent's fiscal Q3 2026 non-GAAP EPS rose 18% year over year to $1.62, beating consensus by 9.46%, while revenue increased 8.1% to $1.88 billion and exceeded estimates by 2.08%. Non-GAAP operating margin expanded 320bps to 28.3% (up 210bps excluding tariff refunds), supported by strong pharmaceutical and China demand, including more than 70% growth in GLP-1-related revenue. The company raised full-year EPS guidance by $0.15 at the midpoint to $6.18-$6.21 and projects fiscal 2026 revenue of $7.49-$7.51 billion; shares have gained 9.6% since the earnings release as analyst estimates moved higher.

Analysis

The key investable signal is not the earnings beat but the quality of the growth mix: recurring services/consumables and high-margin diagnostic workflows reduce Agilent's historical sensitivity to instrument-capex cycles. Sustained order conversion in analytical instruments would also validate a broader recovery for laboratory-equipment peers, particularly Waters (WAT), Bruker (BRKR) and Thermo Fisher (TMO), although Agilent's exposure to pharma QC and clinical diagnostics gives it a cleaner earnings bridge than research-tool names dependent on academic funding.

Near term, the stock has likely absorbed much of the initial estimate-reset upside after its post-results move. The next 1-3 month catalyst is whether Q4 guidance implies that organic growth can remain above 5% without one-off tariff recoveries; that distinction matters because it determines whether operating-margin gains receive a durable multiple rather than being treated as transitory. A slower China recovery, pharmaceutical customers digesting instrument purchases, or a return of book-to-bill below 1.0 would quickly challenge the premium-quality narrative.

The contrarian point is that GLP-1-related laboratory spending is real but can be over-extrapolated: scale-up and validation demand is more equipment-intensive than mature commercial production, where consumables/services dominate. Conversely, the market may underappreciate that expanding installed base today creates multi-year pull-through for CrossLab service contracts and consumables, supporting 6-18 month margin resilience. Debt has risen faster than cash, so incremental M&A or weaker cash conversion would constrain buyback support and merit a lower valuation multiple.

Key Decisions for Investors

• Maintain a modest long A through the next earnings report only if consensus FY2027 organic-growth expectations remain below 5%; use a 7-10% post-results pullback rather than chase momentum. Upside requires confirmation of durable 5%+ core growth and margin expansion excluding nonrecurring items; exit on a sub-1.0 instrument book-to-bill or a material cut to organic-growth guidance.
• Express relative quality with long A / short WAT on a 3-6 month horizon. Agilent's recurring-revenue mix and diagnostic exposure should outperform if pharma spending stays selective; risk-manage if WAT demonstrates comparable order acceleration or if China demand broadens enough to favor its greater cyclicality.
• Monitor TMO and DHR read-throughs for bioprocessing and pharma-capex commentary before adding to A. Broad-based customer capex normalization would support a sector basket, while evidence of GLP-1 validation spending rolling over argues for reducing laboratory-tools beta rather than treating it as an Agilent-specific issue.
• No action in QBTS: it is unrelated to the operating drivers and has no informational read-through from this development.